Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 2261 to 2270 of 2733 total matches.

Herpes Zoster Vaccine (Zostavax)

   
The Medical Letter on Drugs and Therapeutics • Sep 11, 2006  (Issue 1243)
% of adults in the US have had varicella and are at risk for HZ. 1 More than one million new cases of HZ ...
A live attenuated varicella-zoster vaccine (Zostavax - Merck) has been approved by the FDA for prevention of herpes zoster (HZ; zoster; shingles) in persons ≥60 years old. Each dose of Zostavax contains about 14 times as much varicella-zoster virus (VZV) as Varivax, which has been used in the US since 1995 to vaccinate against varicella (chicken pox).
Med Lett Drugs Ther. 2006 Sep 11;48(1243):73-4 |  Show IntroductionHide Introduction

Lubiprostone (Amitiza) for Irritable Bowel Syndrome with Constipation

   
The Medical Letter on Drugs and Therapeutics • Jul 14, 2008  (Issue 1290)
), which was previously approved for treatment of chronic idiopathic constipation in adults, 1 has now ...
Lubiprostone (Amitiza), which was previously approved for treatment of chronic idiopathic constipation in adults, has now also been approved in a lower dose for use in women with irritable bowel syndrome with constipation (IBS-C). Since tegaserod (Zelnorm) has been withdrawn from the market,2 lubiprostone is the only drug approved by the FDA for treatment of this common condition.
Med Lett Drugs Ther. 2008 Jul 14;50(1290):53-4 |  Show IntroductionHide Introduction

Methylnaltrexone (Relistor) for Opioid-Induced Constipation

   
The Medical Letter on Drugs and Therapeutics • Aug 11, 2008  (Issue 1292)
(~50% in urine) Table 1. Pharmacology OPIOID-INDUCED CONSTIPATION — Although patients develop ...
The FDA has approved subcutaneous injection of methylnaltrexone (Relistor - Wyeth/Progenics), a selective mu-opioid receptor antagonist, for treatment of opioid-induced constipation in patients with advanced illness (such as incurable cancer or end-stage chronic obstructive pulmonary disease) who are receiving palliative care.
Med Lett Drugs Ther. 2008 Aug 11;50(1292):63-4 |  Show IntroductionHide Introduction

Edluar - A New Sublingual Formulation of Zolpidem

   
The Medical Letter on Drugs and Therapeutics • Apr 19, 2010  (Issue 1336)
Table 1. Pharmacology *10 mg dose Edluar (Meda), a new sublingual tablet formulation ...
Edluar (Meda), a new sublingual tablet formulation of the benzodiazepine receptor agonist zolpidem (Ambien, and others), has been approved by the FDA for treatment of insomnia.
Med Lett Drugs Ther. 2010 Apr 19;52(1336):29-30 |  Show IntroductionHide Introduction

Ofatumumab (Arzerra) for CLL

   
The Medical Letter on Drugs and Therapeutics • Jun 28, 2010  (Issue 1341)
(Cytoxan, and others) and rituximab (Rituxan). 1 Options for patients who are refractory to initial ...
The FDA has approved ofatumumab (Arzerra – GlaxoSmithKline), a human anti-CD20 monoclonal antibody, for treatment of patients with chronic lymphocytic leukemia (CLL) refractory to fludarabine (Fludara, and others) and alemtuzumab (Campath). It is the second anti-CD20 antibody approved for treatment of CLL; rituximab (Rituxan), a chimeric murine/human antibody, was the first.
Med Lett Drugs Ther. 2010 Jun 28;52(1341):51-2 |  Show IntroductionHide Introduction

Extended-Release Hydrocodone (Zohydro ER) for Pain

   
The Medical Letter on Drugs and Therapeutics • Jun 09, 2014  (Issue 1444)
, and others).1 PHARMACOLOGY — Hydrocodone is a semisynthetic opioid. It is metabolized primarily by CYP3A4 ...
The FDA has approved an extended-release oral formulation of the opioid agonist hydrocodone (Zohydro ER – Zogenix) for management of pain severe enough to require continuous, long-term therapy and for which alternative treatment options are inadequate. Zohydro ER is the first single-ingredient hydrocodone product to be marketed in the US. Hydrocodone has been available for years in combination with acetaminophen (Vicodin, and others) or ibuprofen (Vicoprofen, and others).
Med Lett Drugs Ther. 2014 Jun 9;56(1444):45 |  Show IntroductionHide Introduction

Calcipotriene/Betamethasone Foam (Enstilar) for Psoriasis

   
The Medical Letter on Drugs and Therapeutics • Apr 11, 2016  (Issue 1492)
tolerated than either component alone.1,2 Phototherapy and systemic therapy, including biologic agents ...
The FDA has approved Enstilar (Leo), an aerosol foam formulation of the synthetic vitamin D3 analog calcipotriene and the high-potency corticosteroid betamethasone dipropionate, for topical treatment of plaque psoriasis in adults. Topical ointment and suspension formulations of the same combination have been available for many years.
Med Lett Drugs Ther. 2016 Apr 11;58(1492):48-9 |  Show IntroductionHide Introduction

BioThrax and Anthrasil for Anthrax

   
The Medical Letter on Drugs and Therapeutics • May 09, 2016  (Issue 1494)
such as ciprofloxacin or doxycycline.1,2 Raxibacumab, an intravenous human monoclonal antibody available only ...
The FDA has approved anthrax vaccine adsorbed (AVA; BioThrax – Emergent BioSolutions) for prevention of anthrax disease in adults following exposure to Bacillus anthracis and intravenous anthrax immune globulin (Anthrasil – Emergent BioSolutions) for treatment of inhalation anthrax in adults and children. AVA has been available since 1970 for prevention of anthrax disease in persons at high risk of exposure.
Med Lett Drugs Ther. 2016 May 9;58(1494):62 |  Show IntroductionHide Introduction

Etripamil Nasal Spray (Cardamyst) for Paroxysmal Supraventricular Tachycardia

   
The Medical Letter on Drugs and Therapeutics • Apr 13, 2026  (Issue 1752)
palpitations, dyspnea, chest discomfort, and, rarely, syncope. About 1 in 300 persons in the US are thought ...
The FDA has approved Cardamyst (Milestone), a nasal spray formulation of the nondihydropyridine calcium channel blocker etripamil, for conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. Cardamyst is the first product containing etripamil to be approved in the US. It is being marketed as the only FDA-approved, self-administered, rapid-acting treatment option for acute episodes of PSVT.
Med Lett Drugs Ther. 2026 Apr 13;68(1752):59-61   doi:10.58347/tml.2026.1752b |  Show IntroductionHide Introduction

Opioids for Pain

   
The Medical Letter on Drugs and Therapeutics • Dec 12, 2022  (Issue 1665)
Opioids for Pain A new CDC guideline for prescribing opioids for pain recently became available.1 ...
A new CDC guideline for prescribing opioids for pain recently became available. Nonopioid drugs for pain were reviewed in a previous issue.
Med Lett Drugs Ther. 2022 Dec 12;64(1665):193-200 |  Show IntroductionHide Introduction